To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Recruiting

Phase 3

HAV vs. AVFTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Sponsor:

Humacyte, Inc.

Code:

NCT05908084

Conditions

End Stage Renal Disease (ESRD)

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Acellular Tissue Engineered Vessel (ATEV)

AVF

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Humacyte, Inc. on 2025-03-18.